DexCom, Inc. (NASDAQ:DXCM) Director Sells $222,915.00 in Stock

Key Points

• DexCom Director Mark G. Foletta sold 2,750 shares of the company's stock for $222,915, representing a 5.10% decrease in his ownership of the stock.
• DexCom reported a $0.48 EPS in its latest quarterly earnings, beating the consensus estimate of $0.45, and achieving a year-over-year revenue growth of 15.2%.
• Analysts have given DexCom stock a consensus rating of "Moderate Buy" with an average price target of $99.89, reflecting positive sentiment around the company's stock performance.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

DexCom Price Performance

DXCM traded down $0.13 during trading on Monday, hitting $80.82. 2,976,710 shares of the stock traded hands, compared to its average volume of 3,806,923. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a market cap of $31.69 billion, a price-to-earnings ratio of 56.13, a PEG ratio of 1.70 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The business has a 50 day moving average price of $82.96 and a 200 day moving average price of $79.95.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $0.43 earnings per share. The company's revenue was up 15.2% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DXCM. Raymond James Financial boosted their price objective on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 31st. Citigroup restated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Wall Street Zen cut DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Finally, The Goldman Sachs Group assumed coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $99.89.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of DexCom during the first quarter worth $554,893,000. Norges Bank acquired a new position in shares of DexCom during the second quarter worth $453,279,000. Groupama Asset Managment increased its holdings in shares of DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company's stock worth $350,601,000 after buying an additional 4,011,438 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company's stock worth $576,610,000 after buying an additional 3,410,858 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after buying an additional 2,879,489 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.